TIMOTHY JINKS, PHD

Head, Infectious Disease Interventions, Wellcome

Timothy Jinks was appointed the Head of Infectious Disease Interventions in 2021 where he leads Wellcome’s work in advancing R&D for therapeutics and diagnostics, alongside research to support solutions for antimicrobial resistance. In his previous role, he designed and led Wellcome’s strategic priority area for combatting drug-resistant infections, deploying a budget of over £250 million. Before that, he was responsible for a portfolio of Wellcome projects to support early-stage product development, which covered therapeutics, diagnostics and devices across several therapeutic areas, particularly infectious diseases and oncology. He is a Member of the CARB-X Joint Oversight Committee, Executive Board Member of VALUE-Dx, Member of the Longitude Prize Committee and Representative Member to the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Prior to joining the Trust in 2012, he accumulated over a decade of industry experience both in biologic therapeutic R&D and latterly as a consultant providing business development, licensing and commercial research services. He is a chemist-turned-molecular biologist, who holds a BS Chem from the University of Georgia and a MA and a PhD from Princeton University. In his academic career, he acquired extensive academic research experience at Harvard Medical School, Dana Farber Cancer Institute and the MRC National Institute for Medical Research.